Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib.

Choy EHS, Miceli-Richard C, González-Gay MA, Sinigaglia L, Schlichting DE, Meszaros G, de la Torre I, Schulze-Koops H.

Clin Exp Rheumatol. 2019 Feb 11. [Epub ahead of print] Review.

PMID:
30767864
2.

MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis.

Peterfy C, DiCarlo J, Emery P, Genovese MC, Keystone EC, Taylor PC, Schlichting DE, Beattie SD, Luchi M, Macias W.

J Rheumatol. 2019 Jan 15. pii: jrheum.171469. doi: 10.3899/jrheum.171469. [Epub ahead of print]

3.

Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated Analysis.

Tanaka Y, McInnes IB, Taylor PC, Byers NL, Chen L, de Bono S, Issa M, Macias WL, Rogai V, Rooney TP, Schlichting DE, Zuckerman SH, Emery P.

Arthritis Rheumatol. 2018 Dec;70(12):1923-1932. doi: 10.1002/art.40680. Epub 2018 Oct 22.

PMID:
30058112
4.

Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.

van der Heijde D, Dougados M, Chen YC, Greenwald M, Drescher E, Klar R, Xie L, de la Torre I, Rooney TP, Witt SL, Schlichting DE, de Bono S, Emery P.

RMD Open. 2018 May 8;4(1):e000662. doi: 10.1136/rmdopen-2018-000662. eCollection 2018.

5.

Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.

Taylor PC, Kremer JM, Emery P, Zuckerman SH, Ruotolo G, Zhong J, Chen L, Witt S, Saifan C, Kurzawa M, Otvos JD, Connelly MA, Macias WL, Schlichting DE, Rooney TP, de Bono S, McInnes IB.

Ann Rheum Dis. 2018 Jul;77(7):988-995. doi: 10.1136/annrheumdis-2017-212461. Epub 2018 Feb 20.

6.

Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis.

Genovese MC, Kremer JM, Kartman CE, Schlichting DE, Xie L, Carmack T, Pantojas C, Sanchez Burson J, Tony HP, Macias WL, Rooney TP, Smolen JS.

Rheumatology (Oxford). 2018 May 1;57(5):900-908. doi: 10.1093/rheumatology/kex489.

7.

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis.

Fleischmann R, Alam J, Arora V, Bradley J, Schlichting DE, Muram D, Smolen JS.

RMD Open. 2017 Oct 10;3(2):e000546. doi: 10.1136/rmdopen-2017-000546. eCollection 2017. No abstract available.

8.

Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis.

Keystone EC, Genovese MC, Schlichting DE, de la Torre I, Beattie SD, Rooney TP, Taylor PC.

J Rheumatol. 2018 Jan;45(1):14-21. doi: 10.3899/jrheum.161161. Epub 2017 Aug 15.

9.

Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis.

Kremer JM, Genovese MC, Keystone E, Taylor PC, Zuckerman SH, Ruotolo G, Schlichting DE, Crotzer VL, Nantz E, Beattie SD, Macias WL.

Arthritis Rheumatol. 2017 May;69(5):943-952. doi: 10.1002/art.40036.

10.

Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).

Smolen JS, Kremer JM, Gaich CL, DeLozier AM, Schlichting DE, Xie L, Stoykov I, Rooney T, Bird P, Sánchez Bursón JM, Genovese MC, Combe B.

Ann Rheum Dis. 2017 Apr;76(4):694-700. doi: 10.1136/annrheumdis-2016-209821. Epub 2016 Oct 31.

11.

Baricitinib in Patients with Refractory Rheumatoid Arthritis.

Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, Beattie SD, Koch AE, Cardillo TE, Rooney TP, Macias WL, de Bono S, Schlichting DE, Smolen JS.

N Engl J Med. 2016 Mar 31;374(13):1243-52. doi: 10.1056/NEJMoa1507247.

12.

A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.

Papp KA, Menter MA, Raman M, Disch D, Schlichting DE, Gaich C, Macias W, Zhang X, Janes JM.

Br J Dermatol. 2016 Jun;174(6):1266-76. doi: 10.1111/bjd.14403. Epub 2016 Apr 5.

PMID:
26800231
13.

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.

Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, Lee CH, Fidelus-Gort RK, Luchi ME, Rooney TP, Macias WL, Genovese MC.

Ann Rheum Dis. 2015 Feb;74(2):333-40. doi: 10.1136/annrheumdis-2014-206478. Epub 2014 Nov 27.

14.

Circulating endothelial and endothelial progenitor cells in patients with severe sepsis.

Schlichting DE, Waxman AB, O'Brien LA, Wang T, Naum CC, Rubeiz GJ, Um SL, Williams M, Yan SC.

Microvasc Res. 2011 Mar;81(2):216-21. doi: 10.1016/j.mvr.2010.11.011. Epub 2010 Dec 3.

PMID:
21130783
15.

Destabilizing the 'equipoise' framework in clinical trials: prioritizing non-exploitation as an ethical framework in clinical research.

Schlichting DE.

Nurs Philos. 2010 Oct;11(4):271-9. doi: 10.1111/j.1466-769X.2010.00455.x. Review.

PMID:
20840138
16.

Protein C in critical illness.

Mann HJ, Short MA, Schlichting DE.

Am J Health Syst Pharm. 2009 Jun 15;66(12):1089-96. doi: 10.2146/ajhp080276. Review.

PMID:
19498123

Supplemental Content

Loading ...
Support Center